We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nontoxic QD Nanoparticles Inhibit Cancer Cell Growth

By LabMedica International staff writers
Posted on 29 May 2018
An environmentally friendly method has been developed for the production of quantum dot nanoparticles, which have antimicrobial properties and demonstrate potential for cancer diagnosis and treatment.

Low-dimensional (<10 nanometer) semiconductor quantum dots (QDs) have received great attention for potential use in biomedical applications (diagnosis and therapy) for which larger nanoparticles (>10 nanometers) are not suitable. More...
However, the chemical synthesis of quantum dots is complicated, expensive, and has toxic side effects.

To avoid these toxic effects, investigators at Swansea University (United Kingdom) developed a non-toxic plant-based alternative method of producing quantum dots, using tealeaf extract. Extracts derived from tealeaves (Camellia sinensis) contain a wide variety of compounds, including polyphenols, amino acids, vitamins, and antioxidants. The investigators added tealeaf extract to a mixture of cadmium sulfate (CdSO4) and sodium sulfide (Na2S) and allowed the solution to incubate until quantum dots formed.

The investigators examined the biological activity of these CdS QDs in different applications, namely, (a) antibacterial activity, (b) bioimaging, and (c) apoptosis of lung cancer cells. The antibacterial activity of the CdS QDs was evaluated and showed that CdS QDs effectively inhibited bacterial growth.

The investigators further reported in the March 9, 2018, online edition of the journal Applied Nano Materials that the quantum dots exhibited cytotoxicity toward A549 lung cancer cells when compared to a control (no QD treatment). The cytotoxic effect on A549 cancer cells was comparable to that of a standard drug, cisplatin. Furthermore, these CdS QDs produced high-contrast fluorescence images of A549 cancer cells indicating a strong interaction with the cancer cell.

To further understand the role of CdS QDs in bioimaging and the cytotoxic effect in A549 cells, the investigators performed fluorescence emission and flow cytometry analyses. The flow cytometry analysis confirmed that the CdS QDs were arresting A549 cell growth at the S phase of the cell cycle, inhibiting further growth of these lung cancer cells.

Senior author Dr. Sudhagar Pitchaimuthu, senior research fellow in engineering at Swansea University, said, "Our research confirmed previous evidence that tea leaf extract can be a non-toxic alternative to making quantum dots using chemicals. The real surprise, however, was that the dots actively inhibited the growth of the lung cancer cells. We had not been expecting this. The CdS quantum dots derived from tealeaf extract showed exceptional fluorescence emission in cancer cell bioimaging compared to conventional CdS nanoparticles. Quantum dots are therefore a very promising avenue to explore for developing new cancer treatments. Building on this exciting discovery, the next step is to scale up our operation, hopefully with the help of other collaborators. We want to investigate the role of tealeaf extract in cancer cell imaging, and the interface between quantum dots and the cancer cell. We would like to set up a "quantum dot factory" which will allow us to explore more fully the ways in which they can be used."

Related Links:
Swansea University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
All-in-One Molecular System
AIO M160
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.